ICC tissues; matched adjacent normal tissues; adjacent normal tissues; mouse lung tissues; mouse tumor tissues
HiBEC; QBC-939; HuCCT1; RBE; HCCC9810; HEK293
cell line-derived xenograft
proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); p53 signaling (inhibits); ceRNA regulation (other); ubiquitination (promotes)
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; circRNA-seq; Actinomycin D / DRB Stability Assay; RT-qPCR; RNA-seq; FISH / smFISH; IHC (Immunohistochemistry); Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Co-IP; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; H&E Staining; Western Blot; Cohort Study; Survival Analysis; Bioinformatics Analysis
Elevated circ_0057105 expression correlates with microvascular invasion, advanced TNM stage, shorter OS and DFS, and unfavorable prognosis; it is proposed as a prognostic biomarker and therapeutic target.
circ_0057105 is a PDK1-derived cytoplasmic circRNA that is significantly upregulated in ICC and is associated with aggressive clinicopathological features and poor survival. It promotes ICC proliferation, migration, invasion, tumor growth, and metastasis by sponging miR-1290 to upregulate MDM2, thereby enhancing P53 ubiquitination/degradation and inhibiting the P53 signaling pathway. LNP-mediated si-circ_0057105 delivery suppresses tumor growth in vivo, supporting circ_0057105 as a prognostic biomarker and therapeutic target.
0.9033
Circ_0057105 promotes intrahepatic cholangiocarcinoma progression by sponging miR-1290 and regulating the MDM2/P53 pathway.
combined biological and clinical study